Pacira BioSciences, Inc.

PCRX

US6951271005

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-09-06 pm EDT			5-day change	1st Jan Change
13.85 ^USD	-5.65%		-10.99%	-58.95%

Aug. 13	Truist Securities Downgrades Pacira BioSciences to Sell From Buy, Adjusts Price Target to $8 From $30	MT
Aug. 12	Pacira Biosciences Challenged by Court Ruling on Exparel, 'Uncertain' Prospects, RBC Say	MT

Tranche Update on Pacira BioSciences, Inc.'s Equity Buyback Plan announced on May 7, 2024.

July 30, 2024 at 04:03 pm EDT

From May 7, 2024 to June 30, 2024, the company has repurchased 837,240 shares, representing 1.8% for $25 million. With this, the company has completed the repurchase of 837,240 shares, representing 1.8% for $25 million under the buyback announced on May 7, 2024.

Latest news about Pacira BioSciences, Inc.

Truist Securities Downgrades Pacira BioSciences to Sell From Buy, Adjusts Price Target to $8 From $30	Aug. 13	MT
Pacira Biosciences Challenged by Court Ruling on Exparel, 'Uncertain' Prospects, RBC Say	Aug. 12	MT
Sector Update: Health Care Stocks Flat to Higher Pre-bell Monday	Aug. 12	MT
RBC Capital Downgrades Pacira BioSciences to Sector Perform From Outperform, Cuts Price Target to $14 From $37	Aug. 12	MT
RBC Downgrades Pacira BioSciences to Sector Perform From Outperform, Adjusts Price Target to $14 From $37	Aug. 12	MT
JPMorgan Downgrades Pacira BioSciences to Underweight From Overweight, Adjusts Price Target to $10 From $45	Aug. 12	MT
Raymond James Downgrades Pacira BioSciences to Market Perform From Outperform	Aug. 12	MT
Piper Sandler Downgrades Pacira BioSciences to Neutral From Overweight, Adjusts Price Target to $11 From $42	Aug. 12	MT
Pacira BioSciences Considers Legal Options After Federal Judge Rules Against Patent	Aug. 09	MT
RBC Lowers Price Target on Pacira BioSciences to $37 From $42, Keeps Outperform Rating	Jul. 31	MT
Transcript : Pacira BioSciences, Inc., Q2 2024 Earnings Call, Jul 30, 2024	Jul. 30
Tranche Update on Pacira BioSciences, Inc.'s Equity Buyback Plan announced on May 7, 2024.	Jul. 30	CI
Pacira BioSciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	Jul. 30	CI
Earnings Flash (PCRX) PACIRA BIOSCIENCES Reports Q2 Revenue $178M, vs. Street Est of $173.7M	Jul. 30	MT
Pacira BioSciences, Inc. Reiterates Financial Guidance for the Full Year 2024	Jul. 30	CI
Truist Cuts Price Target on Pacira BioSciences to $30 From $45, Keeps Buy Rating	Jul. 25	MT
Pacira BioSciences, Inc. Announces Centers for Medicare and Medicaid Propose New Reimbursement for EXPAREL in All Outpatient Surgical Environments Beginning January 1, 2025	Jul. 10	CI
RBC Cuts Price Target on Pacira BioSciences to $42 From $45, Keeps Outperform Rating	Jul. 09	MT
Barclays Downgrades Pacira BioSciences to Equalweight From Overweight, Adjusts Price Target to $25 From $38	Jul. 03	MT
Pacira BioSciences Shares Tumble as FDA Approves Exparel Generic	Jul. 02	DJ
Pacira BioSciences, Inc.(NasdaqGS:PCRX) added to Russell Small Cap Comp Value Index	Jun. 30	CI
Pacira BioSciences, Inc.(NasdaqGS:PCRX) added to Russell 2500 Value Index	Jun. 30	CI
Pacira BioSciences, Inc.(NasdaqGS:PCRX) added to Russell 3000 Value Index	Jun. 30	CI
Pacira BioSciences, Inc.(NasdaqGS:PCRX) added to Russell 2000 Value Index	Jun. 30	CI
Pacira BioSciences, Inc.(NasdaqGS:PCRX) added to Russell 2000 Value-Defensive Index	Jun. 30	CI

Chart Pacira BioSciences, Inc.

Duration

Period

More charts

Company Profile

Pacira BioSciences, Inc. is a holding company for Pacira Pharmaceuticals, Inc. The Company's non-opioid treatments include EXPAREL (bupivacaine liposome injectable suspension), which is a long-acting, local analgesic for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), which is an extended-release, intra-articular (IA), corticosteroid injection indicated for OA knee pain, and Iovera, which is a novel handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. EXPAREL is used across multiple orthopedic procedures, including joint reconstruction, shoulder, spine, extremity procedures, and hip fractures. It is developing interventions to address debilitating conditions involving the sympathetic nervous system, such as cardiac electrical storm, chronic pain. Its clinical development programs include PCRX-201, and pMVL-Based Clinical Program.

Employees

712

Sector

Pharmaceuticals

Calendar

2024-10-30 - Q3 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company